University of Mogi das Cruzes
Mogi das Cruzes, São Paulo, 08780911, Brazil
NCT Number: NCT02535858
Anxiety is one of the major influences on relapse and substance abuse treatment dropout. Chemically dependent individuals need to be aware of their emotional state in situations that jeopardise their treatment. The current therapeutic resources still subjective and with limited treatment success. This research presents a developed virtual environment (VE) simultaneously connected to a physiological signals device acquisition that allows, through a biofeedback, the chemically dependents consciousness on their vulnerability front different situations of 'risk', without a direct assessment of the therapist. Developed in 3ds Max® software, the VE is composed of scenarios and objects that are in the habit of the chemically dependent individual's daily life. The interaction with the environment is accomplished using a Human-Computer Interface (HCI) that converts incoming physiological signals indicating anxiety state into commands that change the scenes. Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations. To evaluate the effectiveness of the VE as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled. Prior VE, the results demonstrated a poor correlation between the therapists' predictions and those of the chemically dependent individuals. After exposure to the VE, there was a significant increase of 73% in awareness of the risks of relapse by the chemically dependent individuals, confirming the hypothesis that the VE coupled to the biofeedback device may assist the therapist with treatment.
Looking for future studies?
Notify Me20 year–50 year
Male
Interventional
Not applicable
Mogi das Cruzes, São Paulo, 08780911, Brazil
2.1 Ethical approval Approval was obtained from the Local Ethics Committee (CAAE-0094.0.237.000-07, process CEP/UMC-093/2007) for the participants. They had been informed about the methodology and confidentiality of their personal information. The participants were informed about the methodology and confidentiality of their personal information. All procedures were performed after written informed consent from all participants.
2.2 Study Participants To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication. Three mental health professionals (PG1), specialized in chemical dependency, evaluated the emotional state of the volunteers.
A second group has fifty adult volunteers (DG) (mean age of 35±10.02 years) ongoing outpatient chemical dependency clinic [treatment average's population: 5 months and 14 days]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
For this group, 10 mental health professionals (PG2), therapists, specialized in chemical dependency and responsible for monitoring the group's treatment assessed their emotional states.
To elaborate the scenarios and characterize the characters in the virtual environment (VE), another eight specialists professionals (PG3) from the chemical dependency field recommended situations, places, objects, signs, or cues thought to trigger craving.
2.4 Testing Protocol Prior CDI to the test, the therapist answered a questionnaire identifying the situations of risk presented in the VE that could lead the patient to relapse. The same questionnaire was also completed by the CDI before and after the VE test. In addition, this application was structured based on risk factors survey.
The questions presented are listed below:
The test was conducted in a comfortable room that was part of a therapeutic community for CDIs. This room held the test equipment, a support table for the equipment, and chairs for the patient and therapist. Communication during the test was not recommended. Extra care was taken to avoid tests' interruptions including disturbance caused by equipment (air conditioning, audio, etc.) as well as people entering at the exam room. Regarding the sensors, the cardiac frequency meter was placed on the distal phalanx of the little finger and the respiratory rate (RR) sensor near the right nostril using a headset support. The CDIs were informed that the outcome of each situation presented in the VE would correspond to their physiological state when facing the risk situations. Their questions were answered, and only their emotions were shown to influence the scenarios. The test started with the volunteers watching a desired film selected by themselves where the basal levels from both physiological signals were simultaneously acquired. It was followed by the introduction of the developed VE where both heart and respiratory rates were measured between minutes and compared with the previously acquired baseline levels. The script automatically selected the scenes depending on the identified emotional state. When the state was identified as anxious, the program changed the scene, showing the character using drugs. Otherwise, the plot proceeded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
Time frame: The respiratory and heart rate were collected during 10 minutes from each no-drugs user and 30 minutes from each chemically dependent individual.
This research presents a developed virtual environment (VE) simultaneously connected to a physiological signals device acquisition (heart and respiratory rates) that allows, through a biofeedback, the chemically dependents consciousness on their vulnerability front different situations of 'risk', without a direct assessment of the therapist. During the virtual exposure, the heart and respiratory rates of the chemically dependent individual (CDI) were acquired and processed to be classified as a normal or anxious state. Then, the scenes were automatically changed depending on the captured physiological signals. The signals' average were calculated for each individual and emotional state (normal vs. anxious). A volunteer was considered to be anxious if the heart or respiratory rates are at least 7% and 16% above the basal levels respectively.
University of Mogi das Cruzes
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06942637
Adolescents, Anxiety
Bandung, West Java, Indonesia
View Trial DetailsNCT07739381
Anxiety, Anxiety Disorders
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT07421063
Anxiety, Anxiety Disorders
Bolu, Turkey (Türkiye)
View Trial DetailsNCT05438446
Anxiety, Anxiety Disorders
Athens, Attica, Greece
View Trial Details